10-K: Agilent Technologies Reports 7% Revenue Growth in FY25

Agilent Technologies achieved 7% net revenue growth in fiscal year 2025, reaching $6.95 billion, driven by strong performance in Life Sciences and Diagnostics Markets, alongside strategic restructuring and share repurchases.

Summary

• Net revenue for fiscal year 2025 increased by 7% to $6,948 million, compared to $6,510 million in 2024.
• Foreign currency movements had no impact on revenue growth in 2025.
• The BIOVECTRA acquisition contributed approximately 2 percentage points to the 2025 revenue growth.
• Life Sciences and Diagnostics Markets segment revenue grew by 11% in 2025 to $2,726 million, with BIOVECTRA contributing 5 percentage points.
• Agilent CrossLab segment revenue increased by 6% in 2025 to $2,908 million.
• Applied Markets segment revenue increased by 1% in 2025 to $1,314 million.
• Net income for 2025 was $1,303 million, up from $1,289 million in 2024.
• Cash and cash equivalents increased to $1,789 million as of October 31, 2025, from $1,329 million in 2024.
• The company repurchased and retired 3.4 million shares for $425 million in 2025 under its share repurchase programs.
• Cash dividends of $0.992 per share, totaling $282 million, were declared and paid in 2025.
• A restructuring plan initiated in fiscal year 2025 to optimize management structure incurred $81 million in expenses, with expected annual cost savings of $75 million to $80 million.
• The Singapore tax holiday reduced income taxes by $102 million in 2025, contributing approximately $0.36 to diluted EPS.

Sentiment

Score: 7

Explanation: The company demonstrated solid revenue growth and increased net income for fiscal year 2025, indicating a healthy core business. Strategic restructuring and ongoing investments in R&D and manufacturing capacity are positive for long-term positioning. However, the slight decline in gross and operating margins due to tariffs and costs, coupled with anticipated increases in income taxes in fiscal year 2026 due to new regulations (Pillar Two, OBBBA), suggest potential near-term headwinds. While management is actively mitigating these impacts, the overall picture presents a stable company with both growth drivers and identifiable challenges, leading to a moderately positive sentiment.

Positives

• Achieved 7% net revenue growth in fiscal year 2025, reaching $6,948 million.
• Experienced growth across all three business segments and most key end markets.
• Life Sciences and Diagnostics Markets segment showed strong 11% revenue growth, significantly boosted by the BIOVECTRA acquisition.
• Net income increased to $1,303 million in 2025, demonstrating improved profitability.
• Cash and cash equivalents grew substantially to $1,789 million, enhancing liquidity.
• Benefited from significant tax advantages, including a $57 million federal tax benefit from intra-entity asset transfer, $29 million from foreign-derived intangible income, and a $28 million release of tax reserves.
• The Singapore tax holiday, extended through 2030, provided a $102 million tax benefit in 2025, positively impacting diluted EPS by $0.36.
• Continued commitment to shareholder returns through $425 million in share repurchases and $282 million in cash dividends in 2025.
• Strategic investments in manufacturing capacity expansion for nucleic acid-based therapeutics in Frederick, Colorado, signal future growth potential.

Negatives

• Total gross margin decreased by 2 percentage points in 2025, impacted by higher tariffs, shipping costs, unfavorable business mix (including lower gross margin from specialty CDMO), increased wages, restructuring expenses, and variable pay.
• Operating margin also decreased by 2 percentage points in 2025 due to similar cost pressures.
• Experienced revenue declines in the cell analysis, biomolecular analysis, and genomics businesses within the Life Sciences and Diagnostics Markets segment in certain regions.
• The academic and government market saw revenue declines across all Life Sciences and Diagnostics Markets businesses.
• The Applied Markets segment experienced a modest revenue decline in the chemicals and advanced materials market and a significant decline in the academic and government market.
• Interest income decreased in 2025 primarily due to lower cash balances.
• Interest expense increased in 2025, mainly due to additional interest from new senior notes.
• U.S. federal government headcount and funding reductions adversely impacted business in 2025.
• Recorded unrealized losses of $39 million on equity securities without readily determinable fair value in 2025.
• Incurred $15 million in impairment losses on investments in 2025.

Risks

• General economic conditions, including slower global growth, increasing interest rates, and inflationary pressures, may adversely affect operating results and financial condition.
• Reduced demand, longer sales cycles, increased order cancellations, excess/obsolete inventories, and intensified price pressure could harm profitability.
• International operations are exposed to risks from foreign currency fluctuations, political and economic instability, changes in trade relationships, tariffs, and differing intellectual property protections.
• Failure to timely introduce successful new products and services or adapt to rapid technological changes could lead to product obsolescence and impact revenue.
• Demand for products and services is sensitive to customers' capital spending policies, research and development budgets, and government funding policies, which can fluctuate unpredictably.
• Dynamic government rule-making and policy changes, including tariffs and trade policies, could increase costs, disrupt supply chains, and require operational adjustments.
• Inability to adjust purchases to changing market conditions or accurately estimate customer demand could result in excess and obsolete inventories and additional expenses.
• Failure to retain and hire key research, engineering, sales, marketing, manufacturing, executive, and administrative personnel could hinder business maintenance or expansion.
• Strategic initiatives to adjust cost structure may distract management, slow product improvements, limit production increases, or fail to realize anticipated operational or financial benefits.
• Acquisitions, strategic investments, and alliances may result in unexpected costs, integration difficulties, and failure to achieve anticipated synergies or earnings contributions.
• Consolidation in the life sciences industry could lead to stronger competitors and adversely affect business.
• Public health crises may impact global operations, sales, product delivery, and supply chains.
• Failure to maintain an effective system of internal controls could lead to inaccurate financial reporting and loss of investor confidence.
• Non-compliance with extensive governmental regulations (e.g., FDA, data privacy, anti-bribery, export controls) could result in significant expenses, penalties, product recalls, or business restrictions.
• Environmental contamination from past and ongoing operations could subject the company to substantial liabilities.
• Climate change risks, such as extreme weather events and resource scarcity, may increase operating costs and disrupt manufacturing and distribution.
• Issues in the development, deployment, and use of artificial intelligence technologies, including inaccuracies, biases, intellectual property risks, and evolving regulations, could result in reputational harm or legal liability.
• Claims of intellectual property infringement by third parties could lead to costly litigation, licensing expenses, product redesigns, or injunctions.
• Inability to enforce intellectual property rights effectively could result in competitive injury and lost revenue.
• Manufacturing capacity not matching product demand could lead to adverse effects on gross margins and operating results.
• Dependence on contract manufacturing and outsourcing could adversely affect product delivery and reputation if third parties fail to perform.
• Catastrophic losses to factories, facilities, or distribution systems due to natural disasters or other events could seriously harm operations.
• Significant disruptions or security breaches in information technology systems could adversely affect business and lead to financial or reputational damage.
• Financial market risks impacting retirement and post-retirement pension plans could adversely affect future results and cash flows.
• Changes in tax laws, unfavorable resolution of tax examinations, or exposure to additional tax liabilities could materially affect financial results.
• Cessation or changes in tax incentives could significantly increase income taxes.
• Outstanding debt and future debt incurrence could adversely affect financial condition, liquidity, and results of operations by increasing vulnerability to downturns and reducing cash flow for other purposes.
• The company cannot assure that it will continue to pay dividends on its common stock, which could affect its market price.
• Adverse conditions in the global banking industry and credit markets may impact the value of cash investments or impair liquidity.

Future Outlook

The company remains optimistic about the long-term health of its key end markets and is focused on enhancing customer experience, delivering differentiated product solutions, and driving productivity improvements. It expects to substantially mitigate the adverse impact of recent tariff changes during fiscal year 2026 through supply chain optimization, targeted pricing, and cost-efficiency initiatives. Continued investment in research and development, application and solutions portfolio expansion, and growth in developing and emerging markets are planned. Income taxes are expected to increase in fiscal year 2026 due to the implementation of Pillar Two global minimum tax rules and the U.S. One Big Beautiful Bill Act (OBBBA). Capital expenditures for fiscal year 2026 are projected at approximately $500 million, primarily for expanding nucleic acid-based therapeutics manufacturing capacity.

Management Comments

• "Our primary focus remains on enhancing our customers experience, delivering differentiated product solutions and driving productivity improvements."
• "We remain optimistic about the long-term health of our key end markets."
• "While the recent tariff changes adversely impacted our costs of revenue beginning in the second half of fiscal year 2025, we expect to substantially mitigate the impact during our fiscal year 2026."
• "With inflationary and tariff-related pressures remaining fluid, we are actively pursuing mitigation strategies through supply chain optimization, targeted pricing actions, and other cost-efficiency initiatives to protect margins and sustain long-term growth."
• "The rising demand for several of the modalities provided by our specialty CDMO business positions us well to serve expanding customer demand."
• "By leveraging our liquid chromatography and liquid chromatography mass spectrometry platforms, we are driving growth across key markets and remain optimistic about long-term life sciences opportunities."
• "Our diagnostic and clinical markets continue to grow with the OMNIS platforms."
• "We will continue investing in research and development, advancing our applications and solutions portfolio, and expanding our position in developing and emerging markets."

Industry Context

The life sciences industry is characterized by intense competition, frequent new product introductions, rapid technological changes, and evolving industry standards. Customer demand is significantly influenced by capital spending policies, R&D budgets, and government funding. The company operates within a global regulatory environment with increasing stringency in areas like data privacy (e.g., GDPR, China's PIPL/DSL, CCPA, Brazil's LGPD) and AI, which adds complexity and potential costs. Geopolitical instability and trade regulations, including tariffs and export controls, also pose ongoing challenges to global operations and supply chains.

Comparison to Industry Standards

• The company competes with major players in the Life Sciences and Diagnostics Markets, including AB Sciex (Danaher Corporation), Bruker, Inc., Leica Biosystems, Inc. (Danaher Corporation), Roche Ventana Medical Systems, Inc. (Roche Group), Shimadzu Corporation, Thermo Fisher Scientific Inc., Twist Bioscience Corporation, and Waters Corporation.
• In the Agilent CrossLab and Applied Markets segments, key competitors include Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc., and Waters Corporation, along with numerous niche service providers.
• Competition is primarily based on product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage, and price.
• No specific quantitative benchmarks or direct comparisons of Agilent's financial performance against industry averages or specific competitors' results are provided in the filing.

Management Changes

Corporate Governance

Legal Proceedings

• No matters are pending that are currently believed to be probable and reasonably possible of having a material impact to the business, consolidated financial condition, results of operations, or cash flows.

Related Party Transactions

• The company provides site service costs to, and receives lease income from, Keysight Technologies, Inc. This ongoing relationship contributed $12 million in income in 2025, 2024, and 2023.

Stakeholder Impact

• **Shareholders**: Positive impact from increased net income, continued quarterly dividends, and ongoing share repurchase programs. Potential risks from macroeconomic conditions, tariffs, and operational challenges could affect stock performance.
• **Employees**: Impacted by restructuring plans involving workforce reductions, but also benefit from competitive compensation, equity ownership, and development programs. Management changes affect leadership and organizational structure.
• **Customers**: Benefit from enhanced product solutions, services, and customer experience. Potential for tariff-related cost increases, though mitigation strategies are in place to minimize impact.
• **Suppliers**: May be affected by supply chain optimization and cost-efficiency initiatives. The company maintains long-term relationships to manage technology roadmaps and potential disruptions.
• **Creditors**: The company's financial position appears stable with sufficient liquidity and access to capital markets, supporting its ability to meet debt obligations, although outstanding debt levels are noted.

Next Steps

• Substantially complete FY25 restructuring activities by the second quarter of fiscal year 2026.
• Substantially mitigate the impact of recent tariff changes during fiscal year 2026.
• Continue investing in research and development, advancing application and solutions portfolio, and expanding position in developing and emerging markets.
• Anticipated capital expenditures of approximately $500 million for fiscal year 2026, primarily for expanding manufacturing capacity for nucleic acid-based therapeutics in Frederick, Colorado.
• Expects income taxes to increase in fiscal year 2026 due to Pillar Two global minimum tax rules and the implementation of the U.S. One Big Beautiful Bill Act (OBBBA).
• Expects to contribute $21 million to non-U.S. defined benefit plans during 2026.
• A quarterly dividend of $0.255 per share is scheduled to be paid on January 28, 2026, to shareholders of record as of January 6, 2026.

Key Dates

Recommendation

Agilent Technologies delivered solid revenue growth and increased net income in fiscal year 2025, indicating a healthy underlying business. Strategic initiatives, including a significant acquisition and ongoing investments in R&D and manufacturing, position the company for long-term growth. However, the slight decline in gross and operating margins due to tariffs and other cost pressures, coupled with an anticipated increase in income taxes in fiscal year 2026 from new global and U.S. tax regulations, present near-term headwinds. While management is actively pursuing mitigation strategies, the combination of growth drivers and identifiable challenges suggests a 'hold' recommendation, advising investors to monitor the effectiveness of these strategies and the impact of rising tax burdens on future profitability.

Keywords

Life Sciences, Diagnostics, Applied Markets, Analytical Instruments, Laboratory Solutions, Mass Spectrometry, Chromatography, Genomics, Cell Analysis, CDMO, Pathology, Biopharmaceutical, Pharmaceutical, Environmental, Food Safety, Chemicals, Advanced Materials, SEC Filing, 10-K, Financial Report, Stock Plan, Share Repurchase, Dividends, Restructuring, Tax Incentives, Cybersecurity, AI